PDCD10: A Potential Drug Target for Pancreatic Cancer (G11235)

Target Name: PDCD10

NCBI ID: G11235

PDCD10: A Potential Drug Target for Pancreatic Cancer

PDCD10 (Pancreatic ductal cancer), also known as PDC10_HUMAN, is a protein that is expressed in high levels in pancreatic ductal adenocarcinoma, which is the most common type of pancreatic cancer. PDCD10 has been identified as a potential drug target for pancreatic cancer due to its unique expression pattern and its role in the development and progression of pancreatic cancer.

PDCD10 is a 21-kDa transmembrane protein that is expressed in various tissues, including pancreatic ductal epithelial cells, peritoneal cells, and immune cells. Its expression is highly correlated with the malignant transformation of pancreatic ductal epithelial cells, which is the hallmark of pancreatic cancer. PDCD10 has been shown to promote the malignant transformation of these cells by increasing their responsiveness to oncogenic signaling pathways, such as the TGF-β pathway.

In addition to its role in cancer progression, PDCD10 has also been shown to play a key role in the regulation of pancreatic ductal development and function. It is involved in the development of pancreatic ductal carcinoma, which is the most common type of pancreatic cancer. PDCD10 has been shown to promote the formation of pancreatic ductal carcinoma by suppressing the cell adhesion molecule E-cadherin, which is involved in cell-cell adhesion and tissue patterning.

PDCD10 is also involved in the regulation of pancreatic ductal angiogenesis, which is the process by which new blood vessels are formed in the pancreatic ducts to supply oxygen and nutrients to the growing cancer cells. PDCD10 has been shown to promote the angiogenesis of pancreatic ductal carcinoma by increasing the migration of cancer cells through the blood vessels.

PDCD10 is also associated with the development of pancreatic cancer in humans. Several studies have shown that PDCD10 expression is highly correlated with the poor prognosis of pancreatic cancer patients. PDCD10 has also been shown to promote the development of insulin-dependent diabetes by increasing the insulin resistance of pancreatic epithelial cells, which is a risk factor for type 2 diabetes.

In conclusion, PDCD10 is a protein that has been identified as a potential drug target for pancreatic cancer due to its role in cancer progression, regulation of pancreatic ductal development and function, and association with the development of insulin-dependent diabetes. Further research is needed to fully understand the role of PDCD10 in pancreatic cancer and to develop effective treatments for this aggressive form of cancer.

Protein Name: Programmed Cell Death 10

Functions: Promotes cell proliferation. Modulates apoptotic pathways. Increases mitogen-activated protein kinase activity and STK26 activity (PubMed:27807006). Important for cell migration, and for normal structure and assembly of the Golgi complex (PubMed:27807006). Important for KDR/VEGFR2 signaling. Increases the stability of KDR/VEGFR2 and prevents its breakdown. Required for normal cardiovascular development. Required for normal angiogenesis, vasculogenesis and hematopoiesis during embryonic development (By similarity)

More Common Targets